According to a separate report, mutations in key DDR genes were reported in approximately 10% of the cases in primary tumors, whereas DDR genes were altered in 27% of metastatic cases, confirming that advanced stages of prostate cancer correlate with increasingly higher incidence of mutations in those genes [36]. This evidence concerns the gene DDR1 and prostate cancer.